A Systematic Guideline by the ASPN Workgroup on the Evidence, Education, and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET
Authors:
- Dawood SayedDSDawood Sayed
- Timothy Ray DeerTDTimothy Ray Deer
- Jonathan M HagedornJHJonathan M Hagedorn
- Ryan S D’souzaRDRyan S D’souza
- Christopher M LamCLChristopher M Lam
- Nasir KhatriNKNasir Khatri
- Zohra HussainiZHZohra Hussaini
- Scott G PritzlaffSPScott G Pritzlaff
- Vinicius Tieppo FrancioVFVinicius Tieppo Francio
- Steven Michael FalowskiSFSteven Michael Falowski
Open Access
- 1 April 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 17, 1461-1501
Abstract
Introduction: Painful diabetic neuropathy (PDN) is a leading cause of pain and disability globally with a lack of consensus on the appropriate treatment of those suffering from this condition. Recent advancements in both pharmacotherapy and interventional approaches have broadened the treatment options for PDN. There exists a need for a comprehensive guideline for the safe and effective treatment of patients suffering from PDN. Objective: The SWEET Guideline was developed to provide clinicians with the most comprehensive guideline for the safe and appropriate treatment of patients suffering from PDN. Methods: The American Society of Pain and Neuroscience (ASPN) identified an educational need for a comprehensive clinical guideline to provide evidence-based recommendations for PDN. A multidisciplinary group of international experts developed the SWEET guideline. The world literature in English was searched using Medline, EMBASE, Cochrane CENTRAL, BioMed Central, Web of Science, Google Scholar, PubMed, Current Contents Connect, Meeting Abstracts, and Scopus to identify and compile the evidence for diabetic neuropathy pain treatments (per section as listed in the manuscript) for the treatment of pain. Manuscripts from 2000-present were included in the search process. Results: After a comprehensive review and analysis of the available evidence, the ASPN SWEET guideline was able to rate the literature and provide therapy grades for most available treatments for PDN utilizing the United States Preventive Services Task Force criteria. Conclusion: The ASPN SWEET Guideline represents the most comprehensive review of the available treatments for PDN and their appropriate and safe utilization.Keywords
This publication has 177 references indexed in Scilit:
- Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic NeuropathyJAMA Neurology, 2021
- Opioids for Chronic Noncancer PainJAMA, 2018
- CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016JAMA, 2016
- Psychological therapies for the management of chronic neuropathic pain in adultsCochrane Database of Systematic Reviews, 2015
- Enhanced glucose control for preventing and treating diabetic neuropathyCochrane Database of Systematic Reviews, 2012
- Effectiveness, Tolerability, and Impact on Quality of Life of the 5% Lidocaine Patch in Diabetic PolyneuropathyArchives of Neurology, 2004
- Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDSJAMA, 2004
- Randomized Double-blind Study Comparing the Efficacy of Gabapentin With Amitriptyline on Diabetic Peripheral Neuropathy PainArchives of internal medicine (1960), 1999
- Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes MellitusA Randomized Controlled TrialJAMA, 1998
- Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study GroupArchives of internal medicine (1960), 1991